The University of Chicago Header Logo

Search Result Details

Back to Search Results
This page shows the details of why an item matched the keywords from your search.
Search Results
Ratain, Mark J.
One or more keywords matched the following items that are connected to Ratain, Mark J.
Item TypeName
Concept Costs and Cost Analysis
Concept Cost-Benefit Analysis
Concept Drug Costs
Concept Cost Savings
Concept Health Care Costs
Concept Cost Sharing
Academic Article Other paradigms: better treatments are identified by better trials: the value of randomized phase II studies.
Academic Article A programmable and implantable pumping system for systemic chemotherapy: a performance analysis in 52 patients.
Academic Article Value-based insurance design in oncology.
Academic Article The development of a financial toxicity patient-reported outcome in cancer: The COST measure.
Academic Article User beware: we need more science and less art when measuring financial toxicity in oncology.
Academic Article Measuring financial toxicity as a clinically relevant patient-reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST).
Academic Article Drug-Drug Interactions With Oral Antineoplastic Agents.
Academic Article The Molecular Profiling Lottery: More Accuracy, Less Precision, and No Cost.
Academic Article Interventional Pharmacoeconomics-A New Discipline for a Cost-Constrained Environment.
Academic Article A Cost-Focused Alternative Cancer Medication Dispensing Strategy-"Pack Splitting".
Academic Article Interventional Pharmacoeconomics: A Novel Mechanism for Unlocking Value.
Academic Article Introduction by the Guest Editors.
Academic Article Oncology's "Hockey Stick" Moment for the Cost of Cancer Drugs-The Climate Is About to Change.
Academic Article Near-Equivalence: Generating Evidence to Support Alternative Cost-Effective Treatments.
Academic Article Patient-centered, self-funding dose optimization trials as a route to reduce toxicity, lower cost, and improve access to cancer therapy.
Academic Article Sotorasib dosing and incremental cost ineffectiveness - implications and lessons for stakeholders.
Search Criteria
  • Costs and Cost Analysis